6 research outputs found
Effect of rosiglitazone and pioglitazone treatment on histological grading of ankle lesions during adjuvant-induced arthritis
Animals were treated daily for 21 days with rosiglitazone (ROSI) 10 mg/kg (= 8) or pioglitazone (PIO) 30 mg/kg (= 8) by oral administration. Arthritic (adjuvant-induced arthritis (AIA)) (= 7) and normal controls (= 7) were given 0.5% carboxymethylcellulose alone. Cartilage degradation and bone erosion were graded as indicated in the Materials and methods section. Data are expressed as means ± SEM for five representative animals per group. *, < 0.05 compared with normal controls; , < 0.05 compared with AIA controls (Mann–Whitney test).<p><b>Copyright information:</b></p><p>Taken from "Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis"</p><p>Arthritis Research & Therapy 2008;10(1):R6-R6.</p><p>Published online 16 Jan 2008</p><p>PMCID:PMC2374462.</p><p></p
Effect of rosiglitazone and pioglitazone treatment on expression of PPAR target genes during adjuvant-induced arthritis
Animals were treated daily for 21 days with rosiglitazone (ROSI) 10 mg/kg or pioglitazone (PIO) 30 mg/kg by oral administration. Arthritic (adjuvant-induced arthritis (AIA)) and normal controls were given 0.5% carboxymethylcellulose alone. mRNA levels of adiponectin and peroxisome proliferator-activated receptor (PPAR)-γ normalized to RP29 in adipose tissue were assessed by RT-quantitative polymerase chain reaction. Data are expressed as means ± SEM for three representative samples per group (arthritis score close to the mean score of the group). , < 0.05 compared with AIA controls (ANOVA and Fisher's PLSD post-hoc test).<p><b>Copyright information:</b></p><p>Taken from "Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis"</p><p>Arthritis Research & Therapy 2008;10(1):R6-R6.</p><p>Published online 16 Jan 2008</p><p>PMCID:PMC2374462.</p><p></p
Recommended from our members
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children
BackgroundThis United States-based study compared 2 candidate vaccines: RSV/ΔNS2/Δ1313/I1314L, attenuated by NS2 gene-deletion and temperature-sensitivity mutation in the polymerase gene; and RSV/276, attenuated by M2-2 deletion.MethodsRSV-seronegative children aged 6-24 months received RSV/ΔNS2/Δ1313/I1314L (106 plaque-forming units [PFU]), RSV/276 (105 PFU), or placebo intranasally. Participants were monitored for vaccine shedding, reactogenicity, and RSV serum antibodies, and followed over the subsequent RSV season.ResultsEnrollment occurred September 2017 to October 2019. During 28 days postinoculation, upper respiratory illness and/or fever occurred in 64% of RSV/ΔNS2/Δ1313/I1314L, 84% of RSV/276, and 58% of placebo recipients. Symptoms were generally mild. Cough was more common in RSV/276 recipients than RSV/ΔNS2/Δ1313/I1314L (48% vs 12%; P = .012) or placebo recipients (17%; P = .084). There were no lower respiratory illness or serious adverse events. Eighty-eight and 96% of RSV/ΔNS2/Δ1313/I1314L and RSV/276 recipients were infected with vaccine (shed vaccine and/or had ≥4-fold rises in RSV antibodies). Serum RSV-neutralizing titers and anti-RSV F IgG titers increased ≥4-fold in 60% and 92% of RSV/ΔNS2/Δ1313/I1314L and RSV/276 vaccinees, respectively. Exposure to community RSV during the subsequent winter was associated with strong anamnestic RSV-antibody responses.ConclusionsBoth vaccines had excellent infectivity and were well tolerated. RSV/276 induced an excess of mild cough. Both vaccines were immunogenic and primed for strong anamnestic responses.Clinical trials registrationNCT03227029 and NCT03422237